z-logo
open-access-imgOpen Access
What guidance does HIPAA offer to providers considering familial risk notification and cascade genetic testing?
Author(s) -
Nora B. Henrikson,
Jennifer K. Wagner,
Heather Hampel,
Christopher DeVore,
Nirupama Shridhar,
Janet L. Williams,
Katherine E. Donohue,
Iftikhar J. Kullo,
Anya E. R. Prince
Publication year - 2020
Publication title -
journal of law and the biosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 18
ISSN - 2053-9711
DOI - 10.1093/jlb/lsaa071
Subject(s) - health insurance portability and accountability act , confidentiality , context (archaeology) , internet privacy , genetic testing , medicine , patient confidentiality , protected health information , population , health care , medical emergency , identification (biology) , family medicine , business , nursing , computer security , public health , health policy , computer science , environmental health , paleontology , hrhis , economics , biology , economic growth , botany
Background It is unclear how the Health Insurance Portability and Accountability Act (HIPAA) should be interpreted in the context of sharing of genomic information between family members. Methods The authors analyzed the HIPAA Privacy Rule, reviewed the literature and constructed a clinical scenario to inform how HIPAA can be interpreted for multiple forms of patient- and provider-mediated genetic risk notification. Results Under HIPAA, healthcare providers can lawfully notify relatives to recommend genetic risk assessment using multiple approaches, including supporting the patient telling their own relatives, contacting relatives directly with the patient’s authorization, or contacting a relative’s provider directly. Conclusions Multiple forms of patient- or provider-mediated contact of relatives are already legally permissible under HIPAA, are consistent with ethical obligations of care to patients and their families, and could result in improved population health through identification of clinically actionable disease risk. Unanswered questions remain about implementation and impacts of provider-mediated programs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom